HOME >> BIOLOGY >> NEWS
Can Gleevec help patients with rheumatoid arthritis?

Imatinib mesylate (Gleevec; Novartis) is often the treatment of choice for individuals with either chronic myelogenous leukemia or gastrointestinal stromal tumors. Now, in a study appearing online on September 14 in advance of publication in the October print issue of the Journal of Clinical Investigation, researchers from Stanford University have shown that imatinib can block the development of disease in a mouse model of rheumatoid arthritis (RA), providing hope of a new treatment for RA.

Although there are two documented cases in which individuals taking imatinib to treat their cancer showed clinical improvement in their RA, there had been no study of the effects of imatinib in a mouse pre-clinical model of RA. So, William Robinson and colleagues administered imatinib to mice with an RA-like disease. Imatinib both prevented the onset of disease and the development of established disease. It did this by inhibiting the function of many of the immune cells that contribute to disease in patients with RA. Importantly, imatinib was also shown to inhibit the proliferation of cells taken from the joints of patients with RA. This study indicates that imatinib might provide relief to the many individuals suffering from RA.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
14-Sep-2006


Page: 1

Related biology news :

1. When Gleevec is not enough
2. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent
3. Drug that battles resistance to leukemia pill Gleevec extremely effective against cancer
4. A broken stress response system can contribute to Gleevec resistance
5. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension
6. Next-era targeted therapy overcoming Gleevecs shortcomings
7. New drug sidesteps Gleevec resistance in human trials
8. Abnormal fat metabolism underlies heart problems in diabetic patients
9. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
10. Aggressive therapy best for certain AML patients
11. Investigating antibiotic use in acute care patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/1/2018)... ... August 01, 2018 , ... RURO, Inc., a ... version 7.1. Limfinity® is the software framework that all of RURO’s products are ... both current users and the future of RURO’s laboratory software portfolio. , To ...
(Date:8/1/2018)... ... 2018 , ... Visikol CEO Dr. Michael Johnson has announced that through the ... Visikol will far exceed its original 2018 revenue projections. , Over the last ... pathology tools, whole mount imaging techniques and advanced 3D cell ...
(Date:7/31/2018)... ... July 31, 2018 , ... ... Muzek as Business Development Manager. In this role, Mr. Muzek will lead the ... Lifecycle’s continued growth and expansion. , With over 20 years in business ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ActX ... and is continually updated by a talented scientific team that includes geneticists, PharmD’s, ... , 1. Information on the medical impact of a patient’s genetic variants ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a ... article was published online on August 9, 2018 and will be printed in ...
(Date:8/1/2018)... (PRWEB) , ... August 01, ... ... healer, today announces research results on the significant impact of a proprietary ... responses. , The preclinical research assessed biomarkers for systemic and organ-specific ...
(Date:7/27/2018)... ... July 27, 2018 , ... ... Advocacy Group (BRAG®) and representatives of the Biotechnology Innovation Organization (BIO) met ... recently-issued white paper, “Proposal for a Toxic Substances Control Act (TSCA) Inventory ...
Breaking Biology Technology:
Cached News: